Article
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
Leukemia - 1 Oct 2012
Weisberg E, Liu Q, Nelson Erik, Kung A L, Christie A L, Bronson R, Sattler M, Sanda T, Zhao Z, Hur W, Mitsiades C, Smith R, Daley J F, Stone R, Galinsky I, Griffin J D, Gray N
Abstract excerpt
Acute myeloid leukemia (AML) progenitors are frequently characterized by activating mutations in the receptor tyrosine kinase Fms-like tyrosine kinase-3 (FLT3). Protein tyrosine kinases are integral components of signaling cascades that have a role in both FLT3-mediated transformation as well as viability pathways that are advantageous to leukemic cell survival. The bone marrow microenvironment can diminish AML...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.